Treatment with SIGNIFOR may lead to decreases in circulating levels of cortisol resulting in biochemical and/or clinical hypocortisolism. SIGNIFOR dose reduction or interruption and/or adding…
The right support at the right time
To learn more about what the Novartis Oncology Patient Support Program can offer your patients, call 1-800-282-7630 or visit www.HCP.Novartis.com/Access/.
SIGNIFOR® (pasireotide) Injection, for subcutaneous use
SIGNIFOR is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions:
The most common adverse reactions (frequency ≥20% in either group) occurring in patients receiving SIGNIFOR in clinical trials were:
Please see full Prescribing Information.